Luckin Coffeeの空売り状況は、投資家がLuckin Coffeeの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Luckin Coffee (OTC:LKNCY) 株価情報, 空売り情報

Luckin Coffee Inc is a China based company engaged in operation of coffee stores. It sources its Arabica coffee beans from various suppliers and engage World Barista Champion teams to design its coffee recipes. The company also has partnered with suppliers for other products such as juices and light meals.

LUCKIN COFFEE INC SP/ADR by Luckin Coffee Inc.

Luckin Coffee Inc

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 700 points on Friday.
The Dow traded down 1.63% to 43,457.49 while the NASDAQ fell 1.63% to 19,637.11. The S&amp;P 500 also fell, dropping, 1.38% to 6,033.27.
Check This Out: <a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a>
Leading and Lagging Sectors Consumer staples shares jumped by 0.6% on Friday.
In trading on Thursday, consumer discretionary shares fell by 2.7%.
Top Headline
The S&amp;P Global services PMI dipped to 49.7 in February versus 52.9 in the prior month, down from estimates of 53.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) shares shot up 64% to $0.3286 after the company announced a new strategic acquisition agreement.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>)got a boost, surging 49% to $0.2118.</li>
<li>GDEV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>) shares were also up, gaining 43% to $20.23 after the company announced a one-time special cash dividend of $3.31 per share.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Aspire Biopharma Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares dropped 55% to $2.8000. Aspire Biopharma entered into $3 million senior secured convertible debenture agreement.</li>
<li>Shares of Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) were down 48% to $0.4850.</li>
<li>bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) was down, falling 42% to $4.09. The company announced it agreed to be acquired by Carlyle and SK Capital for a potential total value of up to $9.84 per share.</li>
</ul>
Commodities In commodity news, oil traded down 2.7% to $70.56 while gold traded up 0.1% at $2,957.20.
Silver traded down 1% to $33.140 on Friday, while copper fell 1.4% to $4.5475.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.52%, Germany's DAX 40 fell 0.12% and France's CAC 40 gained 0.39%. Spain's IBEX 35 Index fell 0.12%, while London's FTSE 100 fell 0.04%.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 gaining 0.26%, China's Shanghai Composite Index gaining 0.85%, Hong Kong's Hang Seng Index gaining 3.99% and India's BSE Sensex falling 0.56%.
Economics
<ul>
<li>The U.S. University of Michigan consumer sentiment fell to 64.7 in February compared to a preliminary reading of 67.8.</li>
<li>The year-ahead inflation expectations surged to an over one-year high of 4.3% during February.</li>
<li>U.S. existing home sales fell by 4.9% to an annualized rate of 4.08 million in January, recording the sharpest drop in seven months.</li>
<li>The S&amp;P Global services PMI dipped to 49.7 in February versus 52.9 in the prior month, down from estimates of 53.</li>
<li>The S&amp;P Global manufacturing PMI climbed to 51.6 in February versus 51.2 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43890670/this-unity-software-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ASBP

BLUE

BURU

GDEV

MNDR

Dow Tumbles Over 700 Points; US Services PMI Falls In February

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">West Pharmaceutical Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</h3>
<ul>
<li>On Feb. 13, West Pharmaceutical Services reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72. The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $748.8 million, beating the consensus of $740.47 million. The company's stock fell around 39% over the past month and has a <a href="https://www.benzinga.com/quote/WST">52-week low of $197.01</a>.</li>
<li>RSI Value: 21.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WST Price Action: Shares of West Pharmaceutical gained 2.6% to trade at $208.92 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest WST <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png" alt="" class="wp-image-793688" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-768x705.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Amphastar Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Amphastar Pharmaceuticals will release results for its fourth quarter results, after the market closes on Thursday, Feb. 27, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/AMPH">has a 52-week low</a> of $30.34.</li>
<li>RSI Value: 25.3</li>
<li>AMPH Price Action: Shares of Amphastar Pharmaceuticals fell 0.8% to close at $120.92 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">AMPH stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="857" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png" alt="" class="wp-image-793689" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-300x298.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-768x763.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43890670/this-unity-software-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Long Ideas

AMPH

Top 2 Health Care Stocks That May Rocket Higher This Month

Homebuyers continued to struggle in January as prices sharply rose and the number of home sales in the United States dwindled. Elevated prices have <a href="https://www.benzinga.com/real-estate/24/11/41876775/u-s-homebuyers-are-now-56-on-average-as-younger-generations-struggle-with-wildly-unaffordable-market-housing-expert-warns" target="_blank" rel="noopener">limited many buyers&#8217; ability</a> to purchase homes.
The Data: Sales of previously owned homes fell 4.9% from December to January, <a href="https://www.cnbc.com/2025/02/21/january-home-sales-drop-sharply-as-prices-hit-high.html">according</a> to CNBC, citing the National Association of Realtors. The current level is nearly a 15-year-low for January. The median home price was $396,900, 4.8% higher than last year and the highest price ever for January.
"Mortgage rates have refused to budge for several months despite multiple rounds of short-term interest rate cuts by the Federal Reserve," Lawrence Yun, chief economist for the NAR, told CNBC. "When combined with elevated home prices, housing affordability remains a major challenge."
The average home for sale spent 41 days on the market in January, the longest average period since before the COVID-19 pandemic.
Purchasing with cash also remains popular amid a sustained period of <a href="https://www.benzinga.com/25/02/43873151/mortgage-rates">high mortgage rates</a>. All-cash offers comprised 29% of sales, down from 32% in 2024.
Why it Matters: Many observers have described the U.S. market as <a href="https://www.benzinga.com/real-estate/24/11/41841883/housing-crisis-forces-airbnb-and-vrbo-into-the-hot-seat-as-cities-grapple-with-soaring-rents-and-mounting-public-backlash">undergoing a crisis</a>. Many reports have tied elevated prices to a <a href="https://www.benzinga.com/top-stories/24/06/39512860/us-desperately-needs-housing-supply-so-why-has-new-home-construction-sunk-to-4-year-lows">lack of housing supply</a>.
Beyond affordability, the ripple effects of high housing costs extend throughout the economy. Rising home prices can fuel rent increases, exacerbating financial strain on those unable to buy.
Some experts have called for regulatory changes, <a href="https://www.benzinga.com/real-estate/24/09/41065511/from-single-family-to-many-how-minneapolis-is-zoning-in-on-affordable-housing-but-not-everyone-is-ha">including zoning reforms</a> to encourage new construction. Without intervention, affordability challenges may persist, making homeownership increasingly out of reach for younger buyers and middle-class families.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Economics

Real Estate

Home Sales Decline As Prices Reach All-Time High: Affordability A 'Major Challenge,' Economist Says

Buybacks

PNBK

Patriot National Bancorp Has Received Non-Binding Term Sheets From Investors Seeking To Purchase Shares Of Common Stock And Preferred Stock For An Aggregate Purchase Price Of ~$60M At The Per Share Purchase Price Of The Lower Of $0.75 Per Share Or The Nasdaq Closing Price On The Day Immediately Preceding The Signing Of The Definitive Agreements

Coca-Cola Consolidated's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NYSE">COKE</a>) short percent of float has risen 15.04% since its last report. The company recently reported that it has 68 thousand shares sold short, which is 1.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Coca-Cola Consolidated Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740165328_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Coca-Cola Consolidated has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Coca-Cola Consolidated's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Coca-Cola Consolidated's peer group average for short interest as a percentage of float is 8.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

COKE

Is the Market Bullish or Bearish on Coca-Cola Consolidated?

ZIM Integrated Shipping's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) short percent of float has risen 10.22% since its last report. The company recently reported that it has 16.67 million shares sold short, which is 17.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>ZIM Integrated Shipping Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740165323_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ZIM Integrated Shipping has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ZIM Integrated Shipping's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, ZIM Integrated Shipping's peer group average for short interest as a percentage of float is 2.56%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is ZIM Integrated Shipping Gaining or Losing Market Support?

Clean Harbors's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) short percent of float has fallen 13.79% since its last report. The company recently reported that it has 505 thousand shares sold short, which is 1.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Clean Harbors Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740165317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Clean Harbors has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Clean Harbors's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Clean Harbors's peer group average for short interest as a percentage of float is 7.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Clean Harbors?

WIIM

ConocoPhillips shares are trading lower after the company announced an agreement to sell interest in Ursa, Europa Fields for $735 million to Shell

Payfare Inc. ("Payfare" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAY#TSX">PAY</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/PYFRF#OTCQX">PYFRF</a>) is pleased to announce that the Company's Class A Common shareholders (the "Shareholders") have voted in favour of the previously announced acquisition of Payfare by 1517452 B.C. Ltd. (the "Purchaser"), an affiliate of Fiserv, Inc. (NYSE: FI) ("Fiserv") pursuant to a plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") at the Company's special meeting of Shareholders (the "Meeting") held earlier today.

PYFRF

TSX:PAY

Payfare Announces Shareholder Approval Of Its Acquisition By Fiserv

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures" title="https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures">https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures</a>.

Biotech

General

'Pacemaker Recall: Boston Scientific Corporation Recalls Accolade Pacemaker Devices Due to a Manufacturing Issue That May Lead to Early Device Replacement' - FDA

The Company is providing the following financial results, on a preliminary unaudited basis, for the quarter ended December 31, 2024.

&nbsp;
The Company expects its net loss to be approximately $9.5 million, or approximately $(2.40) basic and diluted loss per share for the quarter ended December 31, 2024, compared to the net income of $0.9 million, or $0.23 basic and diluted earnings per share for the quarter ended December 31, 2023. Book value per share, which is shareholders&#39; equity divided by outstanding shares, is expected to be approximately $1.07 as of December 31, 2024, compared to $11.16 per share as of December 31, 2023. Financial results for the quarter ended December 31, 2024 are expected to be adversely impacted by an expected provision for credit losses of approximately $7.7 million primarily related to two large commercial real estate loans.

Guidance

Patriot National Bancorp Sees Q4 Net Loss ~$(2.40) Down From $0.23 YoY; Book Value Per Share Down To ~$1.07 From ~$11.16 YoY

BABA

BIDU

FUTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCOM

XPEV

Chinese stocks are trading higher amid tech sector optimism and recent stimulus hopes.

The Board of Directors of Federal Signal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) declared a quarterly cash dividend of fourteen cents ($0.14) per share on its common stock. This represents an increase of $0.02 per share, or 17%, compared to the dividend declared in the prior quarter. The dividend is payable on March 27, 2025 to stockholders of record at the close of business on March 14, 2025.

Dividends

Federal Signal Corporation Increases Quarterly Dividend From $0.12 To $0.14 Per Share

<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40985125/bitcoins-on-chain-metrics-are-turning-bullish-what-is-going-on">On-chain data</a> shows Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has maintained its strength comparatively to overall crypto market volatility as a major market move may be imminent.
What Happened: In a post on <a href="https://x.com/glassnode/status/1892866318614905153">X</a> on Friday, analytics provider Glassnode showed meme coins experiencing sharp declines, with TRUMP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) dropping by 33.1% and Shiba Inu (CRYPTO: SHIBA) falling by 27.9%.
Broader drawdowns include Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>), down 6.92%, and Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>), down 6.8%.
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) declined 2.65%, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) slipped 0.84%, outperforming both SOL and meme coins. 
Glassnode also <a href="https://x.com/glassnode/status/1892901010575700134">showed</a> Bitcoin's 1-week realized volatility having dropped to 23.42%, nearing historic lows. Past instances of similar compressions (Oct 2024: 22.88%, Nov 2023: 21.35%) preceded major market moves.
Similarly, BTC's 1-week options Implied Volatility (IV) is at 37.39%, among multi-year lows—suggesting the market is preparing for a volatility expansion. 
Longer-term IV remains elevated (3m: 53.1%, 6m: 56.25%), indicating expectations of significant price swings in the coming months.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43878748/michael-saylor-bitcoin-is-economic-armor-calls-on-us-to-accumulate-btc">Michael Saylor: &#8216;Bitcoin Is Economic Armor&#8217;, Calls On US To Accumulate BTC</a>
Why It Matters: In a post on <a href="https://x.com/NFTdavie/status/1892274326071607698">X</a> on Wednesday, influencer Davie Satoshi said traders should accumulate Bitcoin for building a solid foundation, stacking XRP for stability, adding PEPE to portfolio, and allocating a small portion for the high-risk meme coins with a potential to spike. 
Coinbase CEO Brian Armstrong, in a post on X on Thursday, weighed in on meme coins, acknowledging their <a href="https://www.benzinga.com/25/02/43841212/coinbase-ceo-brian-armstrong-open-to-memecoins-even-if-they-are-low-quality-we-believe-in-free-market-capitalism">cultural impact and potential role in on-chain adoption</a>, creative monetization and financial inclusion. 
Recently, Glassnode data showed <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43811832/is-the-meme-pocalypse-here-dogecoin-shiba-inu-pepe-bonk-open-interest-craters-over-50">meme coin futures open interest</a> down significantly, raising curiosity on the sector&#8217;s upcoming trajectory.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43852658/bitcoin-ethereum-face-downside-risk-as-institutional-demand-fades-jpmorgan-says">Bitcoin, Ethereum Face Downside Risk As Institutional Demand Fades, JPMorgan Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BONK

$BTC

$ETH

$PEPE

$SOL

$TRUMP

Bitcoin Holds Steady, ETH Outperforms SOL, TRUMP, Shiba Inu, Plumment, On-Chain Data Report Shows

Oil is trading lower following a rise in US crude inventories.

21 analysts have expressed a variety of opinions on Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">15</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $379.57, a high estimate of $410.00, and a low estimate of $331.00. Witnessing a positive shift, the current average has risen by 9.24% from the previous average price target of $347.48.
<img src="https://www.benzinga.com/files/images/story/2025/1740164463_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Visa's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$410.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$396.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$383.00</td>
<td>$368.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$393.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Matthew O'Neill</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>John Davis</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$393.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$395.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$363.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$368.00</td>
<td>$322.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$331.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$354.00</td>
<td>$326.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$371.00</td>
<td>$326.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$375.00</td>
<td>$339.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$335.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Visa. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Visa compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Visa's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Visa's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/V/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Visa analyst ratings.</a>
<h2>About Visa</h2>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
<h3>Financial Insights: Visa</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Visa's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 10.15%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Visa's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 53.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Visa's ROE stands out, surpassing industry averages. With an impressive ROE of 13.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.49%, the company showcases effective utilization of assets.
Debt Management: Visa's debt-to-equity ratio is below the industry average. With a ratio of 0.55, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Visa Stock: Analyst Perspectives (21 Ratings)

In the preceding three months, 5 analysts have released ratings for Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Integer Holdings, presenting an average target of $154.4, a high estimate of $163.00, and a low estimate of $145.00. This upward trend is evident, with the current average reflecting a 10.09% increase from the previous average price target of $140.25.
<img src="https://www.benzinga.com/files/images/story/2025/1740164456_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Integer Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$163.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Integer Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integer Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Integer Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Integer Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITGR/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Integer Holdings analyst ratings.</a>
<h2>About Integer Holdings</h2>
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.
<h3>Integer Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Integer Holdings displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.72%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Integer Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 8.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Integer Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.23%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Integer Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.13%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Integer Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.72. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITGR

Demystifying Integer Holdings: Insights From 5 Analyst Reviews

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Innodata and provided 12-month price targets. The average target is $60.5, accompanied by a high estimate of $75.00 and a low estimate of $45.00. This upward trend is evident, with the current average reflecting a 22.22% increase from the previous average price target of $49.50.
<img src="https://www.benzinga.com/files/images/story/2025/1740164448_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Innodata by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Klee</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Innodata. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Innodata compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Innodata's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Innodata's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INOD/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Innodata analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Innodata's Background</h2>
Innodata Inc is a digital services and solutions company. It provides technology and services to information products and online retail destinations. The company has three operating segments: Digital data solutions, Synodex, and Agility. It serves publishers, media and information companies, digital retailers, banks, insurance companies, government agencies, and other industries. Geographically, it operates in the United States, United Kingdom, Netherlands, Canada, and Europe.
<h3>Key Indicators: Innodata's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Innodata showcased positive performance, achieving a revenue growth rate of 135.57% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Innodata's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 33.3%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Innodata's ROE excels beyond industry benchmarks, reaching 45.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Innodata's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.56% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Innodata adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INOD

Demystifying Innodata: Insights From 4 Analyst Reviews

Wall Street analysts rerated Unity Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) after the company reported an <a target="_blank" href="https://www.benzinga.com/25/02/43851464/unity-software-q4-earnings" rel="noreferrer noopener">upbeat quarterly result</a> Thursday amid an exciting earnings season.
Unity&#8217;s fourth-quarter revenue decreased 25% to $457.1 million, which beat&nbsp;the consensus estimate of $433.17 million.
The quarterly loss of 30 cents per share beat the analyst loss estimate of 37 cents per share.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/25/02/43883822/t-mobile-wins-nyc-public-safety-deal-introduces-new-plans-for-first-responders-and-military-families" rel="noreferrer noopener">T-Mobile Wins NYC Public Safety Deal, Introduces New Plans For First Responders And Military Families</a>
Benchmark analyst Mike Hickey upgraded Unity Software from <a target="_blank" href="https://www.benzinga.com/quote/U/analyst-ratings" rel="noreferrer noopener">Sell to Hold</a>.
Citizens Capital Markets analyst Andrew Boone reiterated Unity Software with a Market Perform.
Needham analyst Bernie McTernan maintained Unity Software with a Buy and raised the price target from&nbsp;$26&nbsp;to&nbsp;$33.
Benchmark: Many of Hickey&#8217;s concerns have either materialized or appear to be longer-term potential realizations.
The transition to Vector adds uncertainty in Grow, but AI-driven improvements could help ad performance over time. In Create, Unity 6 adoption and industry growth show promise, though the path to sustained recovery remains unclear.
The shift could cause short-term revenue disruption, and its ability to drive sustainable revenue growth remains uncertain. The incremental cloud costs needed for AI model training may weigh on margins. While Unity expects Vector to position itself as a stronger competitor in mobile advertising, the timeline for material financial benefits remains unclear.&nbsp;&nbsp;
The analyst noted secular challenges in game development from AI remain a significant concern, and emerging as a real competitor in the mobile game market will be exceedingly difficult, given AppLovin Corp&#8217;s continued success and notable lead.
Unity continues to generate cash flow through cost optimization and significant headcount reductions. While the balance sheet remains leveraged, its ability to sustain positive free cash flow despite operational struggles offers some stability. Hickey projected first-quarter revenue of $414 million and EBITDA of $65 million.
Citizens Capital Markets: Unity reported better-than-expected fourth-quarter 2024 results, and while first-quarter 2025 guidance was below expectations, commentary was positive as early adoption of Unity 6 is healthy, Unity is rolling out its next-generation ad platform in the first half of 2025 (ahead of schedule), and margins will likely expand going forward.
Simply put, it feels like it is on the verge of an inflection point in the business under new management as execution is catching up to the quality of the underlying asset as Unity continues to be the creation platform for 70% of the top 1,000 mobile games and 30% of top 1,000 PC games on Steam.
While Boone returned from the call incrementally positive, with shares up 25-30% intra-day, he remained valuation sensitive and awaited a better entry point to move his rating. Boone noted that Vector better utilizes Unity&#8217;s player data from its game engine, which has ~5 billion DAU, while newer models should be more performant as Unity&#8217;s pace of innovation on its ad stack seems to have accelerated.
While the analyst projected Grow Strategic revenue to decline 10% year over year, Unity is obviously only moving to a more performant model. He noted that the revenue stepdown will likely prove conservative and temporary. Interestingly, Unity noted that it believes a broader opportunity exists beyond core gaming user acquisition as it works on programmatic brand-focused capabilities, while eCommerce is a long-term opportunity, the analyst highlighted. Boone projected first-quarter revenue of $414.9 million and EBITDA of $64.3 million.
Needham: McTernan arrived at the valuation using a higher target multiple on lower estimates, reflecting a better understanding of the path to improving the Grow business with the launch of Vector. The analyst expects the first quarter of 2025 to be the year&#8217;s low point, with integrations and algo improvements driving the Grow business back to low-single-digit growth in the second half of 2025.
Ultimately, algo performance will drive the Grow business, and there remains a high level of uncertainty, but he noted that he is setting a conservative bar at this point. McTernan projected first-quarter revenue of $410.2 million and EBITDA of $60.3 million.
U Price Action: U stock is up 1.57% at $28.44 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43883619/uscellular-q4-earnings-3-99-million-postpaid-connections-churn-drops-to-1-29-withholds-2025-guidance-due-to-t-mobile-deal" target="_blank" rel="noreferrer noopener">UScellular Q4 Earnings: 3.99 Million Postpaid Connections, Churn Drops To 1.29%, Withholds 2025 Guidance Due To T-Mobile Deal</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Upgrades

Price Target

Reiteration

Unity Hits An Inflection Point? Analysts Highlight Accelerated Innovation In Gaming And Advertising

e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) underwent analysis by 27 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">15</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $132.85, a high estimate of $170.00, and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.03%. 
<img src="https://www.benzinga.com/files/images/story/2025/1740164438_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive e.l.f. Beauty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patty Kanada</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$124.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Patty Kanada</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$120.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$131.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$158.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Patty Kanada</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$133.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to e.l.f. Beauty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of e.l.f. Beauty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for e.l.f. Beauty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of e.l.f. Beauty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ELF/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on e.l.f. Beauty analyst ratings.</a>
<h2>About e.l.f. Beauty</h2>
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.
<h3>Breaking Down e.l.f. Beauty's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: e.l.f. Beauty's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 31.14%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: e.l.f. Beauty's net margin is impressive, surpassing industry averages. With a net margin of 4.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): e.l.f. Beauty's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.38%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

27 Analysts Assess e.l.f. Beauty: What You Need To Know

Press Releases

Luckin Coffee Files Audited Financial Statements for Fiscal Year 2023

Luckin Coffee to Announce First Quarter 2024 Financial Results on April 30, 2024

Earnings

Luckin Coffee Inc. Announces First Quarter 2024 Financial Results

Management

Luckin Coffee Inc. Announces Change to Board of Directors

Luckin Coffee to Announce Second Quarter 2024 Financial Results on July 30, 2024

Luckin Coffee Inc. Announces Second Quarter 2024 Financial Results

Luckin Coffee to Announce Third Quarter 2024 Financial Results on October 30, 2024

Luckin Coffee Inc. Announces Third Quarter 2024 Financial Results

Luckin Coffee to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Luckin Coffee Announces Fourth Quarter and Fiscal Year 2024 Financial Results

LKNCY

Luckin Coffee

Comments

Luckin Coffee

空売り

Luckin Coffee (OTC:LKNCY) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル